Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Palivizumab in Indian Children at High Risk of Severe RSV Disease
NCT06851806Phase 4Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of palivizumab in respiratory syncytial virus infection (RSV), sponsored by AstraZeneca. Started Dec 2025; status: active, not recruiting.
02
Drugs
palivizumab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06851806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06851806.